Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer

British Journal of Surgery

Volumn 87, Issue 1, 2000, Pages 43-48

  Kobari, M ^a   Egawa, S ^a   Shibuya, K ^a   Sunamura, M ^a   Saitoh, K ^a   Matsuno, S ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CANCER SURVIVAL; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MULTIVARIATE ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; SURVIVAL RATE;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTRAOPERATIVE CARE; KILLER CELLS, LYMPHOKINE-ACTIVATED; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; POSTOPERATIVE CARE; SURVIVAL ANALYSIS;

EID: 0033987888     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2000.01336.x     Document Type: Article

References (25)

1. 1 Kobari M, Sunamura M, Ohashi O, Saitoh Y, Yusa T, Matsuno S. Usefulness of Japanese staging in the prognosis of patients treated operatively for adenocarcinoma of the head of the pancreas. J Am Coll Surg 1996; 182: 24-32.
2. 2 Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988; 208: 215-20.
3. 3 Gotoh M, Monden M, Sakon M, Kanai T, Umeshita K, Ikeda H et al. Intraoperative irradiation in resected carcinoma of the pancreas and portal vein. Arch Surg 1992; 127: 1213-15.
4. 4 Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
5. 5 Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59:2006-10.
6. 6 Japan Pancreas Society. Classification of Pancreatic Carcinoma. 1st English ed. Tokyo: Kanahara, 1996.
7. 7 Kobari M, Asano H, Yusa T, Matsuno S. Effects of LAK-adoptive immunotherapy for pancreatic cancer. Journal of the Japan Pancreas Society 1991; 6: 22-30.
8. 8 Kobari M, Hisano H, Matsuno S, Sato T, Kan M, Tachibana T. Establishment of six human pancreatic cancer cell lines and their sensitivities to anti-tumor drugs. Tohoku J Exp Med 1986; 150:231-48.
9. 9 Westerdahl J, Andrén-Sandberg Å, Ihse I. Recurrence of exocrine pancreatic cancer - local or hepatic? Hepatogastroenterology 1993; 40: 384-7.
10. 10 Uchida A, Hoshino T. Clinical studies in cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 1980; 45: 476-83.
11. 11 Takeda K, Fujii N, Nitta Y, Sakihara H, Nakayama K, Rikiishi H et al. Murine minor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6. Jpn J Cancer Res 1991; 82: 1299-308.
12. 12 Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-97.
13. 13 Bar MH, Sznol M, Atkins MB, Ciobanu N, Micetich KC, Boldt DH et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 1990; 8: 1138-47.
14. 14 Wakisaka Y, Uchino Y, Hosokawa M, Une Y, Nakajima Y, Kawada S. A comparison between the effectiveness of chemoimmunotherapy and chemotherapy in preventing cancer recurrence in resected hepatocellular carcinoma patients. Japanese Journal of Cancer Clinics 1992; 38: 841-8.
15. 15 Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 1992; 127: 1343-9.
16. 16 Rosenberg SA. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2. Semin Oncol 1986; 13: 200-6.
17. 17 Amikura K, Kobari M, Matsuno S. The time of occurrence of liver metastasis in carcinoma of the pancreas, Int J Pancreatol 1995; 17: 139-46.
18. 18 Kühl JS, Klapdor R, Mohr H, Arps H, Dietel M. Cytokines and pancreatic cancer. The effect of rIFN-gamma, HuLeIFN, rTNF-alpha, and LAK cells on pancreatic and other gastrointestinal tumours in vitro, Int J Pancreatol 1989; 4: 207-19.
19. 19 Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD Jr. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model. Surgery 1990; 108: 919-29.
20. 20 Marincola FM, Drucker BJ, Keeling CA, Siao DY, Starnes HF Jr, Goodwin DA et al. The in vitro distribution of human peripheral blood lymphocytes and lymphokine-activated killer cells adoptively transferred in human pancreatic cancer-bearing nude mice. Surgery 1989; 105: 79-85.
21. 21 Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 1985; 135: 4273-80.
22. 22 Keilholz U, Schlag P, Tilgen W, Brado B, Galm F, Görich J et al. Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer 1992; 69:2172-5.
23. 23 Westerdahl J, Radnell C, Ingvar C, Cay O, Jeppsson B, Segén S et al. IL-2 perfusion of experimental hepatic metastases. Journal of Experimental Clinical Cancer Research 1994; 13: 83-8.
24. 24 Chen L, Ashe S, Brady WA, Hellström KE, Ledbetter JA, McGowan P et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-102.
25. 25 Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155: 1393-403.